Please select the eligibility criteria that correspond to the clinical trial below.
Title: Long-Acting Reversible Contraception: New Research to Reduce Unintended Pregnancy
Brief Summary: In the proposed study, women aged 18-29 seeking oral or injectable contraception will be offered an opportunity to try LARC instead; the FDA-approved options include two types of intrauterine products and one type of subdermal contraceptive implant. Over a 24 month period, the experiences of LARC users will be compared to the experiences of those opting for their initial short-acting method.


Options:
A: Inclusion Criteria:

* All reproductive age women who express a desire for the LNG-IUS (Mirena©) at routine questioning at their 36-38 week prenatal appointment or upon admission to labor and delivery are eligible for our study.

Exclusion Criteria:

* Contraindications to the LNG-IUS include: Pregnancy or suspicion of pregnancy, Congenital or acquired uterine anomaly including fibroids if they distort the uterine cavity, Postpartum endometritis within the past 3 months, Known or suspected uterine or cervical neoplasia or unresolved, abnormal pap smear, untreated acute cervicitis or vaginitis including bacterial vaginosis or other lower genital tract infections, acute liver disease or liver tumor, hypersensitivity to any component of the product, known or suspected carcinoma of the breast. Any of these conditions would exclude the patient from our study.
* Delivery \<36 weeks
* Intrapartum chorioamnionitis (defined as maternal fever \>100.4 and two of the following conditions: Maternal leukocytosis (greater than 15,000 cells/cubic millimeter), Maternal tachycardia (greater than 100 beats/minute), Fetal tachycardia (greater than 160 beats/minute), Uterine tenderness, Foul odor of the amniotic fluid
* Postpartum Hemorrhage (defined as \>500cc EBL for spontaneous vaginal delivery)
* Cesarean delivery if randomized to IPP or EP placement
B: Inclusion Criteria:

* 18 to 29 years of age;
* sexually active;
* seeking oral or injectable contraception;
* working cell phone;
* working email account;
* willingness to be contacted by the clinic staff or study coordinators; and,
* willingness to complete questionnaires.

Exclusion Criteria:

* currently pregnant;
* previous use of a long-acting reversible contraceptive (LARC) method; and,
* medical contraindications for oral contraceptives and injectables.
C: Inclusion Criteria:

* Females desiring contraception by using intrauterine device following their vaginal delivery or cesarean section

Exclusion Criteria:

* refusal to participate in the study
* desiring other methods of contraception
* will not use any method of contraception
* has a contraindication for the use of IUD as bicornuate or septate uterus, sub mucous myomas, etc.
D: Inclusion Criteria:

* Women who desire to use the ENG implant as a contraceptive method and desire to breastfeed her newborn for ate least 3 months;
* With no contraindication to breastfeeding, whose newborn is healthy, without malformations, born at term (gestational age ≥ 37 weeks), with appropriate weight for gestational age and with normal sucking ability

Exclusion Criteria:

* Tobacco smokers, drug addicts or alcoholics;
* Women with educational levels lower than 5 years;
* Women with clinical conditions considered category 3 and 4 for implant use by the WHO;
* Women with histories of psychiatric illness;
* Women using medications that could alter the concentration of ENG,
* Women with known allergies to the local anesthetic lidocaine (used to place the implant);
* Women who wanted to keep their cyclic menstrual bleeding

Answer: B